Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1893 in obstructive hypertrophic cardiomyopathy
NCT06516068Phase 2Active, not recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-1893 in hypertrophic cardiomyopathy (HCM), sponsored by Shandong Suncadia Medicine Co., Ltd.. Started Aug 2024; status: active, not recruiting.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06516068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516068.